We report a patient with Ph-positive CML who developed a Ph-negative AML in donor cells 14 months after BMT from an HLA-identical male unrelated donor. The Ph translocation could not be detected by either conventional cytogenetics, FISH or RT-PCR analysis excluding relapse of CML in myeloid blast crisis. Chimerism studies were performed by variable number of tandem repeats (VNTR) analysis. These revealed donor-type hematopoiesis in both unseparated mononuclear cells and CD34
Donor cell leukemia (DCL) is a rare event of unknown incidence after allogeneic stem cell transplantation (SCT). A total of 19 cases of DCL after allogeneic SCT from HLA-compatible siblings have been described in the literature since 1971 (review Refs 1-3). The mechanisms leading to DCL are not understood 3 and treatment modalities are not yet established. Despite its rarity cases of donor cell leukemia are considered of great interest, as they may provide insights into mechanisms of leukemogenesis. 1, 4 To our knowledge, we report the first case of a donor cell leukemia developing after bone marrow transplantation from a 
Materials and methods

RNA isolation and cDNA synthesis
Total RNA was extracted with Trizol (Gibco BRL, Life Technologies, Karlsruhe, Germany) from 10 6 to 10 7 PBMC. RNA was transcribed into cDNA in a 20 l reaction with MMLV-reverse transcriptase using random hexamer primers under standard conditions.
Nested RT-PCR for bcr-abl
The nested RT-PCR was performed as described by Maurer et al. 5 Amplification from the b2a2 variant and the b3a2 variant result in amplification products of 320 bp and 395 bp, respectively.
Chimerism analysis by the use of VNTR
DNA was isolated from 10 7 PBMC by Quiagen columns using QIAamp blood kit (Hilden, Germany) as described by the manufacturer. Template DNA at a concentration of 0.05 g/l was amplified by PCR for VNTR analysis at D1S80 using the AmpliFLP D1S80 PCR Amplification Kit (Perkin Elmer, Langen, Germany).
CD34 selection by magnetic cell sorting
PBMC were isolated by Ficoll density centrifugation. CD34 + cells were purified by magnetic cell sorting using the MACS CD34 Progenitor Cell Isolation Kit (Miltenyi Biotec, Bergisch Gladbach, Germany) and the MiniMACS separation system following the recommended protocol.
FISH analysis of sex chromosomes
Fluorescence in situ hybridization was performed after fixing in methanol/glacial acetic acid (4:1) and hybridization in Cep Hybrid buffer (Vysis, Stuttgart, Germany) at 37°C overnight with the X and Y chromosome-specific probes Spectrum Green and Spectrum Orange, respectively (Vysis).
Case report
Philadelphia chromosome-positive CML in first chronic phase was diagnosed in September 1996 in a 38-year-old male. He was initially treated with hydroxyurea and IFN␣ and achieved hematological remission. In November 1998 he underwent allogeneic BMT from an HLA-identical matched unrelated male donor after conditioning with busulfan (4 mg/kg p.o. daily for 4 days), cyclophosphamide (60 mg/kg i.v. daily for 2 days) and ATG (30 mg/kg i.v. daily for 3 days). 2.2 × 10 8 /kg fresh nucleated bone marrow cells were infused after red blood cell depletion (blood group: recipient O Rhesus positive, donor A Rhesus positive). No further graft manipulation was performed. Methotrexate and cyclosporin A were administered for GVHD prophylaxis. G-CSF was given to enhance neutrophil recovery. A neutrophil count of Ͼ0.5 × 10 9 /l was achieved by day 17. Engraftment of donor marrow was confirmed by VNTR analysis. The patient developed acute GVHD grade II of the skin which responded to treatment with prednisolone. In the further post-transplant period the patient developed several complications, including severe hemorrhagic cystitis, which only resolved after intravesical instillation of prostaglandin, and recurring CMV viremias (12/98 +3/99), responding to ganciclovir and foscarnet. In March 1999, he developed CMV retinitis of both eyes which partially resolved with intravenous therapy with ganciclovir and foscarnet.
In January 2000 a drop in the platelet count (from 90 × 10 9 /l to 51 × 10 9 /l within 2 months) was noted without other clinical problems. The white cell count was 3.2 × 10 9 /l and the blood film showed 4% blasts. The bone marrow was infiltrated by about 10% blasts identical to those in the peripheral blood. The blasts were strongly positive for peroxidase and Sudan black and negative for PAS and ␣-naphtylacetatesterase. This was consistent with acute myeloid leukemia, FAB M2. Immunophenotyping using FACS analysis revealed the blasts to be CD34, HLA-DR, CD33, CD13, MPO and CD7 positive. Cytogenetic analysis of the bone marrow showed a normal karyotype 46 XY (18 metaphases analyzed). There was no evidence for fusion of bcr and abl on FISH analysis. No t(8;21), inv(16) or t(15;17) could be detected at the molecular level. RT-PCR for bcr-abl was negative. VNTR analysis showed complete donor chimerism in the bone marrow as well as in the peripheral blood (Figure 1 ). The CD34 positivity enabled enrichment of the blasts by magnetic cell sorting with a purity of CD34 + cells of у90%. This subset of cells was again donor type on VNTR analysis and was negative for bcr-abl by RT-PCR (Figure 2 ). The donor was healthy at the time of the bone marrow harvest and had not developed any hematological abnormalities up to the last follow-up 25 months later.
Since the patient was in good general condition, chemotherapy was given as treatment for the AML. He received three courses of mitoxantrone, (12 mg/m 2 daily i.v. on days 1 and 2), topotecan (1.75 mg/m 2 daily i.v. on days 3-7) and 6 Post-transplant immunosuppression consisted of cyclosporin A and mycophenolate mofetil. The patient was discharged on day 2 after the transplant and was treated in our outpatient clinic. Complications included CMV reactivation and limited chronic GVHD. Nine months after the second transplant the patient is still in complete remission. T cell chimerism was studied by sex chromosome analysis and revealed complete female donor chimerism.
Discussion
The development of DCL after allogeneic SCT is a very rare event. The donor cell origin of leukemia arising after BMT might be underestimated since chimerism analysis is often difficult and cytogenetic studies alone are sometimes misleading. 7 In our case the first donor and recipient were of the same gender requiring molecular analysis of chimerism. The exclusive demonstration of donor-type DNA in both CD34
+ and unselected cells unequivocally demonstrated that in our patient the 'recurrent' leukemia developed in donor cells.
Currently 19 cases of DCL have been described in the literature since 1971 (review Refs 1-3), including 13 cases of ALL and six of AML. All patients had received allografts from HLA-compatible sibling donors. Diagnosis of DCL occurred between 2 months and 11 years, with a median of 24 months, after transplantation. At 14 months our patient falls in this range.
Contrary to expectation the analysis of DCL has provided few insights into leukemogenesis. DCL may develop in the host or may be transferred by transplantation of malignant cells which are either not sufficiently transformed or which are under immunological control in the healthy donor. These cells may expand under the conditions of immunosuppression. We have no evidence for transmission of a leukemia, which has been reported in only one case previously. 8 However, in our case the DCL lacked specific molecular markers which could have allowed detection of an aberrant clone in the donor. Our patient is the first reported case of a DCL after unrelated BMT suggesting that genetic familiar disposition is not the only risk factor for this rare event.
Very few results of treatment of DCL have been described in the literature. Out of six cases of donor cell AML, 1,9-13 only two had had CML as the original disease. 1, 12 In these two cases the patients died of septic complications after induction chemotherapy. One AML patient received a second stem cell transplant from the same donor after induction therapy with daunomycin and stayed in remission for at least 11 months. 10 Our patient entered CR after the first of three courses of chemotherapy and experienced only minimal complications. He regenerated with donor hematopoiesis after a modest delay. To induce a GVL effect against the donor leukemia cells, we undertook a second allogeneic stem cell transplant from an alternative female donor. To reduce cumulative toxicity we chose a non-myeloablative conditioning regimen which was very well tolerated. These results indicate that chemotherapy and a second SCT from an alternative donor can be successful in patients with DCL.
